PT - JOURNAL ARTICLE AU - Anne-Sophie Archambault AU - Younes Zaid AU - Volatiana Rakotoarivelo AU - Étienne Doré AU - Isabelle Dubuc AU - Cyril Martin AU - Youssef Amar AU - Amine Cheikh AU - Hakima Fares AU - Amine El Hassani AU - Youssef Tijani AU - Michel Laviolette AU - Éric Boilard AU - Louis Flamand AU - Nicolas Flamand TI - Lipid storm within the lungs of severe COVID-19 patients: Extensive levels of cyclooxygenase and lipoxygenase-derived inflammatory metabolites AID - 10.1101/2020.12.04.20242115 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.04.20242115 4099 - http://medrxiv.org/content/early/2020/12/07/2020.12.04.20242115.short 4100 - http://medrxiv.org/content/early/2020/12/07/2020.12.04.20242115.full AB - BACKGROUND Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) is the infectious agent responsible for Coronavirus disease 2019 (COVID-19). While SARS-CoV-2 infections are often benign, there are also severe COVID-19 cases, characterized by severe bilobar pneumonia that can decompensate to an acute respiratory distress syndrome, notably characterized by increased inflammation and a cytokine storm. While there is no cure against severe COVID-19 cases, some treatments significantly decrease the severity of the disease, notably aspirin and dexamethasone, which both directly or indirectly target the biosynthesis (and effects) of numerous bioactive lipids.OBJECTIVE Our working hypothesis was that severe COVID-19 cases necessitating mechanical ventilation were characterized by increased bioactive lipid levels modulating lung inflammation. We thus quantitated several lung bioactive lipids using liquid chromatography combined to tandem mass spectrometry.RESULTS We performed an exhaustive assessment of the lipid content of bronchoalveolar lavages from 25 healthy controls and 33 COVID-19 patients necessitating mechanical ventilation. Severe COVID-19 patients were characterized by increased fatty acid levels as well as an accompanying inflammatory lipid storm. As such, most quantified bioactive lipids were heavily increased. There was a predominance of cyclooxygenase metabolites, notably TXB2 >> PGE2 ∼ 12-HHTrE > PGD2. Leukotrienes were also increased, notably LTB4, 20-COOH-LTB4, LTE4, and eoxin E4. 15-lipoxygenase metabolites derived from linoleic, arachidonic, eicosapentaenoic and docosahexaenoic acids were also increased. Finally, yet importantly, specialized pro-resolving mediators, notably lipoxin A4 and the D-series resolvins, were also found at important levels, underscoring that the lipid storm occurring in severe SARS-CoV-2 infections involves pro- and anti-inflammatory lipids.CONCLUSIONS Our data unmask the important lipid storm occurring in the lungs of patients afflicted with severe COVID-19. We discuss which clinically available drugs could be helpful at modulating the lipidome we observed in the hope of minimizing the deleterious effects of pro-inflammatory lipids and enhancing the effects of anti-inflammatory and/or pro-resolving lipids.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Cheikh Zaid Foundation awarded to YZ and grants from the Canadian New Frontier Research Fund (NFRN-2019-00004) awarded to LF (PI), EB (co-PI) and NF (co-PI) and the Natural Sciences and Engineering Research Council of Canada awarded to NF. ASA received a doctoral award from the Canadian Institutes of Health Research. EB is recipient of a doctoral award from the Fonds de Recherche du Quebec en Santé (FRQS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Local Ethics Committee of Cheikh Zaid Hospital in Rabat Morocco, by the local Ethics Committee of Institut universitaire de cardiologie et de pneumologie de Quebec-UL and by the local Ethics Committee of CHU de Quebec-UL. The study complies with the Declaration of Helsinki and all subjects signed a consent form.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the paper and its Supporting Information files.